real peptides FAQ

Request three documents: (1) HPLC chromatogram showing the purity percentage and retention time, (2) mass spectrometry report confirming the molecular weight matches the intended sequence, (3) Certificate of Analysis (CoA) stating endotoxin levels and storage conditions. If a supplier provides only an HPLC percentage without the chromatogram or MS confirmation, assume the purity claim is based on area-under-curve alone and may include co-eluting contaminants. Real Peptides provides all three documents for every batch, accessible through the product page by entering the lot number printed on the vial.

Incomplete dissolution typically indicates either degraded peptide, incorrect pH of the reconstitution buffer, or contamination with insoluble byproducts from synthesis. Gently swirl the vial (never shake. Shaking denatures peptide structure) and allow 2–3 minutes for dissolution. If particulates remain, the peptide is likely compromised. Real Peptides' quality control includes solubility testing in standard reconstitution buffers (bacteriostatic water, sterile saline) to verify complete dissolution within 90 seconds at room temperature. Competitors using bulk synthesis may ship peptides with residual salts or incomplete purification that precipitate upon reconstitution.

Discard the vial immediately. Cloudiness indicates protein aggregation or contamination, meaning the peptide structure has degraded and biological activity is compromised. Aggregated peptides can trigger immune responses in cell cultures or animal models, introducing confounding variables into your research. Contact the supplier with the batch number for a replacement. Real Peptides tests reconstitution clarity pre-sale specifically to prevent this, but temperature excursions during shipping can still cause aggregation in any peptide.

Do not use it. Cloudiness or particulate matter indicates protein aggregation, contamination, or incomplete dissolution. All of which mean the peptide is no longer suitable for research applications. Aggregated SNAP-8 cannot be 'fixed' by additional mixing or filtration. Once the tertiary structure collapses into aggregates, the biological activity is lost. Discard the vial and reconstitute a fresh one using proper technique.

If the peptide remained frozen (check for ice crystals in the vial or surrounding packaging), it's likely fine. Lyophilised peptides tolerate brief temperature increases as long as they don't fully thaw and reabsorb moisture. If the vial reached room temperature and stayed there for more than 12 hours, degradation may have started. Consider replacing it if the research requires high confidence in dose accuracy.

VIP and TNF-α blockers work through fundamentally different mechanisms. TNF-α inhibitors (e.g., infliximab, etanercept) neutralise one cytokine after it's already been produced. They don't prevent its synthesis or modulate the immune cells producing it. VIP, by contrast, prevents cytokine transcription by inhibiting NF-κB nuclear translocation. The practical difference: VIP reduces multiple cytokines simultaneously (TNF-α, IL-6, IL-12, IFN-γ) rather than targeting one. If your model shows partial efficacy with a TNF-α blocker, adding VIP may address the residual inflammatory pathways that the biologic misses.

VIP is stable as a lyophilised powder at −20°C for up to two years. Once reconstituted with bacteriostatic water, stability drops to 28 days at 2–8°C. Any temperature excursion above 8°C accelerates peptide degradation. Even brief exposure (e.g., leaving the vial on a benchtop for 3–4 hours) can reduce bioactivity. If you suspect potency loss, run a dose-response curve comparing fresh reconstituted VIP to stored VIP using a quantifiable endpoint (e.g., IL-6 production in LPS-stimulated macrophages). A rightward shift in the dose-response curve indicates reduced potency. Aliquot reconstituted VIP into single-use vials immediately after mixing to minimise freeze-thaw cycles, which denature the peptide structure.

Use a validated cold chain shipping container with gel packs pre-conditioned to −20°C for lyophilised peptides or 2–8°C for reconstituted solutions. Include a temperature data logger to verify the vial stayed within range during transit. Standard styrofoam coolers lose temperature control within 6–8 hours. Purpose-built peptide shippers maintain stability for 48–72 hours.

Withdraw the needle, invert the vial, and use a fresh sterile syringe to carefully draw out the excess air through the rubber stopper. Insert the needle, allow air to escape until you see liquid at the needle hub, then withdraw. Excess air creates positive pressure inside the vial, which forces solution out through the needle track when you attempt future draws and increases contamination risk. It also accelerates oxidative degradation of the peptide by increasing the air-to-liquid interface area inside the vial.

Discard the vial immediately. At room temperature (20–25°C), peptides degrade at 10–20× the rate they do at 4°C. An eight-hour overnight exposure reduces potency by 30–50%, and there's no way to test this at home. Repeating research with degraded peptide wastes more resources than replacing one vial.

Aliquot the reconstituted solution into smaller sterile vials (0.5–1.0mL each) and freeze the extras at −20°C. Frozen reconstituted peptides remain stable for 3–6 months, though each freeze-thaw cycle degrades potency by 5–10%. Thaw only what you need for each experiment and never refreeze a thawed aliquot.

Freeze aliquots at −20°C immediately after reconstitution, then thaw only what you need for each experiment—never refreeze a thawed aliquot. KLOW freeze-thaw testing measures activity loss across repeated cycles; peptides that pass this test tolerate aliquot-based storage without significant degradation. If your peptide wasn't freeze-thaw validated, assume each cycle costs you 10–15% potency and plan accordingly.

Combining Dihexa and P21 in a single protocol introduces mechanistic synergy. Dihexa builds new synaptic connections while P21 protects existing neurons from oxidative and inflammatory damage that could otherwise limit Dihexa's structural gains. No published studies have formally tested this combination, but the pathways are non-competitive: HGF/c-Met signaling and CNTF-like JAK/STAT activation operate through distinct receptor systems with minimal crosstalk. Researchers exploring this combination typically stagger administration. P21 in the acute phase (first 72 hours) to establish neuroprotective conditions, followed by Dihexa for 14–28 days to maximize synaptogenesis in a metabolically stable environment. Dosing would follow independent ranges for each peptide, with monitoring for additive effects on inflammatory markers and synaptic density via histological or imaging endpoints.

Reconstitute a fresh aliquot from the original lyophilised batch and retest immediately—if activity returns, the issue is storage degradation, not synthesis quality. KLOW longitudinal data would have predicted this timeline by tracking purity loss across refrigerated storage intervals. Peptides without oxidative stability testing often show this pattern: initial potency followed by gradual functional decline that researchers mistake for receptor desensitisation or experimental drift.

Use a validated cold-chain transport container that maintains 2–8°C for the entire transit duration. Most laboratory-grade peptide coolers use phase-change materials or gel packs pre-conditioned to 4°C. These maintain the target range for 24–48 hours depending on ambient temperature. Never transport reconstituted peptides in a standard insulated bag with ice packs, as ice packs at 0°C can cause localized freezing at the vial wall, which denatures peptides just as effectively as heat exposure.

Confirm receptor expression first. VIP acts through VPAC1 and VPAC2. If your target tissue or cell type lacks functional receptor expression, the peptide won't bind. Use RT-PCR or immunohistochemistry to verify receptor presence before concluding the peptide is ineffective. If receptors are present but effects are minimal, check dosing and timing. VIP has a plasma half-life of ~2 minutes, but receptor-mediated effects persist for 4–6 hours. Administer VIP 30–60 minutes before inducing inflammation (e.g., before LPS challenge or antigen exposure) to allow receptor occupancy before the inflammatory trigger.

This indicates aggregation driven by improper pH or solvent incompatibility—do not inject or use the solution. KLOW workability protocols test solubility across multiple reconstitution solvents to prevent this exact failure mode. If your peptide wasn't validated in bacteriostatic water but you used it anyway, aggregation is the expected outcome. Switch to the validated solvent listed in the product specification, or request workability data from your supplier if none was provided.

Dihexa's effects are dose-dependent and require sufficient time for synaptogenesis to translate into functional connectivity changes. If no effect is observed at 14 days, the protocol likely underdosed or used an inadequate endpoint. Synaptic density changes are measurable via histology or PET imaging, but behavioral endpoints (spatial memory tasks, novel object recognition) require 21–28 days to stabilize. Rodent studies showing robust effects used doses of 0.5–5 mg/kg daily; human-equivalent dosing (approximately 0.04–0.4 mg/kg) remains theoretical. Lack of effect may also indicate that the subject's baseline synaptic density was already optimal. Dihexa amplifies plasticity capacity, but if the limiting factor is neurotransmitter availability or metabolic function, Dihexa alone will not compensate.

P21 becomes the priority compound in contexts of active neuroinflammation. Its CNTF-mimetic properties directly reduce microglial activation and pro-inflammatory cytokine release, which Dihexa does not address. Administering Dihexa into an inflamed neural environment may limit efficacy: chronic inflammation impairs BDNF signaling and reduces dendritic spine stability, effectively undermining the structural changes Dihexa is meant to induce. Published research on Cerebrolysin (P21's parent compound) shows that CNTF-like signaling must precede or coincide with synaptogenic interventions to maximize benefit. In practical terms: if inflammatory markers (elevated IL-6, TNF-α) are present, P21 should be administered first to normalize the environment before introducing Dihexa.

Combine Humanin and SS-31 in a protective protocol targeting both apoptotic prevention and membrane stabilization. Humanin at 2–5 mg daily prevents stress-induced mitochondrial destruction, while SS-31 at 1–2 mg/kg twice weekly stabilizes existing cardiolipin structures that would otherwise deteriorate with age. This combination mirrors the approach used in gerontology research focused on healthspan extension. Preventing both acute mitochondrial loss (Humanin) and chronic structural decay (SS-31). The protocol becomes particularly relevant after age 50, when endogenous Humanin levels drop below the threshold required for adequate mitochondrial protection.